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Abstract
The expectation that genomics would result in new therapeutic
interventions for infectious diseases remains unfulfilled. In the
post-genomic era, the decade immediately following the availability
of the genome sequence of Mycobacterium tuberculosis, tuberculo-
sis (TB) drug discovery relied heavily on the target-based approach
but this proved unsuccessful leading to a return to whole cell
screening. Genomics underpinned screening by providing knowl-
edge and many enabling technologies, most importantly whole
genome resequencing to find resistance mutations and targets,
and this resulted in a selection of leads and new TB drug candi-
dates that are reviewed here. Unexpectedly, many new targets
were found to be ‘promiscuous’ as they were inhibited by a variety
of different compounds. In the post-post-genomics era, more
advanced technologies have been implemented and these include
high-content screening, screening for inhibitors of latency, the use
of conditional knock-down mutants for validated targets and
siRNA screens. In addition, immunomodulation and pharmaco-
logical manipulation of host functions are being explored in an
attempt to widen our therapeutic options.
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Introduction
Genomics was supposed to revolutionize drug discovery and lead to
numerous new therapeutic interventions. The use of bioinformatics
for identifying potential drug targets that were restricted to selected
pathogens, absent from humans and readily validated genetically
was certainly appealing. In the area of anti-infectives, genomics has
been largely disappointing as many of the rationally chosen new tar-
gets have transpired to be intractable, non-essential during disease
or simply undruggable (Payne et al, 2007). Tuberculosis (TB) drug
discovery has also suffered from the overoptimism inspired by the
post-genomics revolution but, unlike other infectious disease areas,
reasonable progress has been achieved nonetheless. Here, we will
illustrate how genome-derived methods have underpinned TB drug
discovery efforts, conducted mainly through whole-cell screening
methodologies, and provided enabling technologies and valuable
knowledge about the etiologic agent, Mycobacterium tuberculosis
(Mtb). The limitations of classical whole-cell screening have led to
the creation of more sophisticated screens in the post-post-genomics
era and these will be discussed in this review.
Tuberculosis as a global health problem
With 8.7 million new active cases in 2011 and mortality of 1.4
million, TB remains an enormous global health problem (Zumla
et al, 2013b). The success of Mtb is due to a perfect adaptation to the
environment of its major host, the human macrophage. Mtb circum-
vents the bactericidal immune response and persists intracellularly
after shutting down its own metabolism (Gengenbacher & Kauf-
mann, 2012). It is estimated that one-third of the world’s population
is afflicted byMtb latent infection, meaning that viable but ‘dormant’
bacteria are contained within granulomas of these individuals
although there is growing evidence for a spectrum of different bacte-
rial physiological states contributing to subclinical TB (Robertson
et al, 2012). Immune suppression leads to reactivation of the disease,
explaining the high TB burden in people living with HIV and AIDS.
To avoid antibiotic resistance, it is mandatory to administer com-
bination therapy comprising rifampicin, isoniazid, pyrazinamide and
ethambutol for 2 months followed by 4 months of rifampicin and
isoniazid to treat active TB. Despite this, drug resistance is an alarm-
ing problem and multi-drug resistant (MDR-TB) and extensively drug
resistant strains (XDR-TB) are on the rise (Zumla et al, 2013b). Thus,
the development and implementation of new drugs is a major
keystone for future control of TB. The past decade has seen some
success here since several promising compounds are in pre-clinical
and clinical trials (Zumla et al, 2013a). Notably, in 2012, the diaryl-
quinoline bedaquiline became the first FDA-approved anti-TB drug
in more than 40 years (Zumla et al, 2013a).
The desirable attributes of a new TB drug are numerous and,
ideally, include activity against both replicating and non-replicating
bacteria, and penetration within tissues and granulomas — eventu-
ally leading to shortening of treatment duration. A new drug should
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have a novel target or mechanism of action allowing for treatment
of MDR- and XDR-TB, and, most challengingly, be compatible with
other anti-TB agents and drugs for treating comorbidities such as
HIV/AIDS or diabetes. Patients co-infected with HIV-TB may receive
>6 drugs including anti-HIV and anti-TB medications, thereby
increasing the potential side-effects of drug-drug interactions and
posing an enormous logistical challenge for the clinician.
Considerable effort has been made in recent years in the hunt for
new medicines that would improve TB treatment and subsequent
disease control. Four principal approaches have been followed:
(i) discovering new drug candidates, (ii) repurposing existing anti-
microbials, (iii) modulating host functions to increase cure rates,
and (iv) developing innovative modes of drug administration. Only
the first and third of these will be discussed in detail.
TB drug research in the post-genomic era
Since 1998 when the first complete genome sequence of Mtb
became available (Cole et al, 1998), genomics has provided a
valuable drug discovery resource by catalyzing genetic manipula-
tion and spawning powerful technologies including micro-array-
based transcriptomics, proteomics, comparative genomics and
structural genomics. These post-genomic advances impacted our
understanding of Mtb biology considerably (Lew et al, 2011) and
facilitated subsequent drug target identification and validation.
However, many of the targets that were validated as being
essential in vitro by genetic means, such as gene replacement or
saturation transposon mutagenesis (Sassetti et al, 2003), proved
not to be required during infection due to genetic redundancy or
metabolic scavenging, leading us to appreciate that pharmacological
target-validation was far more reliable and a better predictor of
success.
TB drug discovery can follow two main routes (Sala & Hartkoorn,
2011): the drug-to-target or the target-to-drug approaches (Fig 1).
All the current drugs and candidates in clinical trials were derived
from a drug-to-target path involving high throughput screening
against whole cells, highlighting the importance of this approach.
However, post-genomic tools now support the target-to-drug
route and we will provide examples illustrating this area of research
too.
In the late 90’s whole genome sequencing (WGS) of bacteria was
slow, extremely costly and labour-intensive. Nowadays, next gener-
ation sequencing platforms are widely available and WGS is used
intensively to identify single nucleotide polymorphisms (SNP) or
other mutations in the genome of spontaneous drug-resistant
mutants allowing for target identification of novel compounds
(Table 1). However, with some hit compounds generating resistant-
Mtb mutants is not possible, making target identification and valida-
tion problematic. In these cases, post genomics tools have again
been successfully used to give further insight into mechanism of
action. For instance, using transcriptional profiling, before and after
Glossary
Cidality
the ability or power to kill microrganisms
Compound penetration
the ability or power of a drug to penetrate into tissues
Cytokine
proteins or peptides involved in cell signaling. Usually involved in the
immune response and immune modulation
Gene replacement
replacing the copy of the gene originally present with an altered
version
Granuloma
a focal, compact collection of inflammatory cells in which various
types of immune cells surround an undegradable
product (pathogen, foreign bodies or hypersensitivity reaction). The
center of granulomas due to Mtb often contains necrotic material
Latent infection
presence of Mtb without symptoms and signs of active disease
Lysosome
acidic cell organelles that break down cellular debris and foreign
particles such as bacteria
Phagosome
a cellular compartment which is formed out of the cell membrane
when foreign bodies such as bacteria are taken up by a phagocytic
cell (e.g. a macrophage)
Phenotypic screen
a drug screen that results in an altered phenotype of an organism or
cell e.g. growth inhibition or death
Promiscuous target
A single target to which multiple pharmacophores bind but not
necessarily at the same site
Protein kinases
enzymes that posttranslationally modify proteins through
phosphorylation
Rational drug design
drug-like molecules are designed or selected for the modulation of a
specific and known target (usually an enzyme) using structural
information
Repurposed drugs
drugs against molecules developed and marketed for one clinical
condition that are used for another
Single nucleotide polymorphism (SNP)
change of a single nucleotide in genomic DNA. If the affected region
codes for a protein, SNPs can lead to amino acid changes. If it lies in
the promoter region it may increase or decrease gene expression
Targeted drug screen
uses a validated target to find inhibitors
Transposon mutagenesis
Insertion of a transposon into a gene in order to inactivate it and
possibly confer a mutant phenotype
Whole-cell high throughput screen
trial and error screening of huge libraries of small molecule on
cultured bacteria or infected cells using robotics
Whole genome sequencing (WGS)
deciphering the complete DNA sequence of an organism. Used to find
SNPs an other mutations
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drug exposure, resulted in the identification of mycobacterial
gene expression signatures that correlate with mechanism of action
(Boshoff et al, 2004).
Although more elegant in terms of applied biology, the target-to-
drug approach has been unsatisfactory mainly because converting
the ability of a compound to inhibit a purified enzyme (IC50) into
potency against whole cells (minimal inhibitory concentration: MIC)
has proved a formidable obstacle to rational drug design. Promising
enzyme inhibitors generally have poor, if any, activity against the
bacterium itself, and this is presumably due to the complex myco-
bacterial cell envelope preventing uptake, to the action of efflux
pumps or to compound inactivation. In addition, compound pene-
tration alone does not always explain the lack of correlation
between IC50 and MIC. For example, the level of protein inhibition
needed to cause cidality is another important issue and can vary
widely between targets (Wei et al, 2011).
From drug…
• Potential antimycobacterial
 molecules
• Compound libraries 
…to drug
• Validation against M.tuberculosis 
 and MIC/MBC determination
• Preclinical development: 
 lead optimization, medicinal 
 chemistry, in vivo studies
From target…
• Identification and validation
 of a potential drug target
…to target
• Target identification and 
 validation
• Preclinical development:
 lead optimization, medicinal 
 chemistry, in vivo studies
in vitro activity
• Lead identification
• MIC/MBC determination
• Cytotoxicity
enzyme inhibition
• Enzyme expression and
 purification
• Enzyme-based screening (IC50)
• 3D structure determination
• Fragment-based screening
A
B
Figure 1. TB drug discovery: from drug-to-target (A) and from target-to-drug (B).
The figure displays the two main distinct methodologies in the search for new TB drugs. It is noteworthy that a target identified after a chemical screen (A) can enter the
target-to-drug pipeline in enzyme-based screening (B). MIC, minimal inhibitory concentration; MBC, minimal bactericidal concentration; IC50, half maximal inhibitory
concentration.
Table 1. Targets identified by whole genome sequencing.
Target gene Drug/Inhibitor Sequencing technology Reference
atpE Bedaquiline (TMC207) 454 Andries et al (2005)
ddn PA-824 NimbleGen Manjunatha et al (2006)
ddn Delamanid (OPC67683) Not specified Matsumoto et al (2006)
dprE1 BTZ043 ABI-Sanger Makarov et al (2009)
dprE1 DNB1 ABI-Sanger Christophe et al (2009)
dprE1 VI-9376 ABI-Sanger Magnet et al (2010)
dprE1 377790 Illumina Stanley et al (2012)
dprE1 TCA1 Illumina Wang et al (2013)
inhA Pyridomycin Illumina Hartkoorn et al (2012)
mmpL3 SQ109 Illumina Tahlan et al (2012)
mmpL3 AU1253 SOLiD Grzegorzewicz et al (2012)
mmpL3 THPP Illumina Remuinan et al (2013)
mmpL3 Spiro Illumina Remuinan et al (2013)
mmpL3 BM212 Illumina La Rosa et al (2012)
mmpL3 C215 Illumina Stanley et al (2012)
qcrB Q203 Illumina Pethe et al (2013)
qcrB IP3 Illumina Abrahams et al (2012b)
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Some of the clinically most advanced candidates are molecules
with known MIC that were originally developed to treat other infec-
tious diseases but have been repurposed for TB. These include com-
pounds from the rifamycin, fluroquinolone and oxazolidinone
classes, whose properties have been extensively reviewed elsewhere
(Ma et al, 2010; Zumla et al, 2013a).
How the classical drug-to-target pathway led to potential new TB
drugs
Screening chemical libraries for compounds with MIC against live
mycobacteria has delivered several promising TB drug candi-
dates: the nitroimidazoles (PA-824 and delamanid), bedaquiline
(TMC207), the newly identified imidazopyridine amide compound
Q203, the diethylamine SQ109, and the benzothiazinone BTZ043
(Table 2).
The related bicyclic nitroimidazoles, PA-824 and delamanid, are
successes of the post-genomic era. Both nitroimidazoles are highly
active against Mtb in aerobic conditions and against non-replicat-
ing or hypoxic bacteria (Stover et al, 2000; Matsumoto et al,
2006). Their mechanism of action was first thought to be due to
inhibition of mycolic acid biosynthesis but is now known to be
more complex. Manjunatha et al used microarray-based genome
sequencing (Table 1) to identify mutations associated with resis-
tance to PA-824 (Manjunatha et al, 2006). Interestingly, mutations
affecting a nitroimidazo-oxazine specific nitroreductase, called Ddn
(deazaflavin-dependent nitroreductase), confer resistance to both
PA-824 and delamanid (Manjunatha et al, 2006). Ddn activates both
these nitroimidazoles resulting in intracellular release of nitric oxide
that presumably kills the bacteria (Singh et al, 2008). Gene expres-
sion profiling analysis after PA-824 exposure revealed activation of
genes involved in cell wall synthesis as well as in respiration, sug-
gesting that PA-824 indeed inhibits both pathways (Manjunatha
et al, 2009).
In 2005, using a classical phenotypic screen, Andries et al (2005)
discovered a very potent molecule, TMC207 or bedaquiline, an inno-
vative, recently-approved drug candidate that offers considerable
hope for curing MDR-TB cases. Through WGS, these investigators
identified four missense mutations, associated with bedaquiline-resis-
tance, in the c subunit of the mycobacterial ATP synthase encoded by
atpE and then confirmed this as the drug target. However, a subse-
quent genetic study of spontaneously acquired TMC-207 resistant
mutants revealed that only 15 out of 53 mutants harbored such muta-
tions in atpE (Huitric et al, 2010) suggesting that the drug has either
additional targets or resistance mechanisms, such as drug efflux. The
discovery of bedaquiline highlighted energy metabolism in general
and ATP synthase inhibition in particular as highly druggable.
Very recently, Pethe and colleagues further validated the proton-
motive force and ATP synthesis as a major TB drug target with the
discovery of a new class of imidazopyridine amide compounds that
block growth of Mtb by targeting the respiratory cytochrome bc1
complex (Pethe et al, 2013). Using phenotypic high-content screen-
ing of infected macrophages (described in detail later), a series of
compounds were selected and chemically optimized culminating in
Q203, an inhibitor active at nanomolar concentrations with promis-
ing efficacy in murine TB models. Spontaneous-resistant mutants,
subjected to WGS, harbor a single amino acid substitution in the
cytochrome b subunit of the cytochrome bc1 complex associated with
imidazopyridine amide-resistance. This innovative target is an essen-
tial component of the electron transport chain required for ATP
synthesis and a second inhibitor of cytochrome b has also been reported
(imidazo[1,2-a]pyridine (IP3); Table 1; Abrahams et al, 2012b).
The primary target of SQ109, a diethylamine drug candidate that
inhibits mycolic acid synthesis (Protopopova et al, 2005), was only
recently identified as MmpL3, a transmembrane transporter of tre-
halose monomycolate (Tahlan et al, 2012). Initially, the investiga-
tors were unable to identify spontaneous SQ109-resistant mutants;
Table 2. Main new chemical entities in development as antituberculosis drugs.
Drug/Inhibitor Class of drug
Hit identification
strategy
Mechanism(s) of
action
Mechanism(s) of
resistance
Target(s)
confirmed Main reference(s)
PA-824 Nitroimidazoles Whole-cell screening
of metronidazole
derivatives
Inhibition of cell wall
synthesis and
interference with cell
respiration by
NO production
Mutation in the
nitroreductase
Ddn required for
pro-drug activation
No Manjunatha et al
(2006, 2009)
OPC-67683 Nitroimidazoles Whole-cell screening
for mycolic acid
biosynthesis inhibitors
Inhibition of mycolic
acid synthesis
and NO production
Mutation in the
nitroreductase
Ddn required for
pro-drug activation
No Matsumoto et al
(2006)
TMC207 Diarylquinoline Whole-cell screening
from quinolone
derivatives
Inhibition of ATP
biosynthesis
Mutation in the c
subunit of Atp
synthase, other(s)?
Yes Andries et al (2005)
Q203 Imidazopyridine
amide
Phenotypic screen
in infected
macrophages
Inhibition of the
cytochrome
bc1 complex
Mutation in the b
subunit of the
cytochrome
bc1 complex
Yes Pethe et al (2013)
SQ109 Diethylene
diamine
Whole-cell screening
of ethambutol
derivatives
Inhibition of mycolic
acid biosynthesis,
other(s)?
Mutation in
MmpL3
Yes Protopopova et al
(2005); Tahlan
et al (2012)
BTZ043 Benzothiazinone Whole-cell
screening
Inhibition of
arabinogalactan
biosynthesis
Mutation in
DprE1
Yes Makarov et al
(2009)
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however, using ethylenediamine analogues, resistant mutants were
generated that showed cross-resistance to SQ109 and WGS revealed
mutations in the mmpL3 gene. Interestingly, many other MmpL3
inhibitors have been found and amongst these are the adamantyl
urea compound (AU1235), which is structurally related to SQ109
(Grzegorzewicz et al, 2012), and the benzimidazole C215 (Stanley
et al, 2012). MmpL3 appears to be a ‘promiscuous’ target that is
inhibited by diverse, chemically unrelated compounds. This is fur-
ther exemplified by the recent discovery of BM212 (La Rosa et al,
2012) as well as tetrahydropyrazolo[1,5-a]pyrimidine-3-carboxa-
mide and the spiro compounds (N-benzyl-6′,7′-dihydrospiro[piperi-
dine-4,4′-thieno[3,2-c]pyran] analogues) that also target MmpL3
(Remuinan et al, 2013).
Benzothiazinones (BTZ), a new class of sulphur containing het-
erocyclic compounds, are extremely potent against Mtb, displaying
low nanomolar bactericidal activity in vitro and in intracellular
infection models (Makarov et al, 2009). Genetic and biochemical
studies, as well as transcriptomic and proteomic analyses, identified
the DprE1 subunit of the essential enzyme decaprenylphosphoryl-b-
D-ribose 2′-epimerase as the target. Inhibition of DprE1 abolishes
arabinogalactan synthesis, eventually leading to cell lysis. This
actinobacteria-specific target was further validated when it was
found to be inhibited by other nitro-aromatic molecules, dinitro-
benzamides (Christophe et al, 2009), VI-9376 (Magnet et al, 2010)
and the nitro-substituted triazole, 377 790 (Stanley et al, 2012), and
by TCA1, a small molecule inhibitor with no nitro group (Wang
et al, 2013). DprE1 also appears to be a promiscuous target.
Rare examples of rational drug design — from target to drug
Despite the considerable effort invested, the target-based approach
has had very limited impact on the discovery of novel TB drugs
(Sala & Hartkoorn, 2011). Here, we discuss some of the more prom-
ising results obtained from structure-guided inhibitor design with
two well-understood systems.
Ethionamide (ETH) is an approved second-line drug but with
considerable side effects (Weinstein et al, 1962) that inhibits the
enoyl-ACP reductase, InhA, the target of isoniazid (INH), thus pre-
venting mycolic acid synthesis (Banerjee et al, 1994). ETH is a pro-
drug activated by the mono-oxygenase EthA, whose expression is
repressed by EthR (Baulard et al, 2000). Activation and, in turn,
potency of the drug are limited by low constitutive levels of EthA.
EthR inhibition leads to EthA overproduction and increases the
activity of ETH against Mtb. Drug-like inhibitors of EthR, such as
BDM31343, were designed using the crystal structure as a template
and these boost ETH activity, improve its therapeutic index and tri-
ple its potency in mice (Willand et al, 2009).
The glyoxylate shunt is an important metabolic pathway for Mtb
physiology, since it is upregulated in the absence of glycolysis to
maintain the tricarboxylic acid cycle during the persistent phase of
infection (McKinney et al, 2000). Mammals lack the two major
enzymes in the pathway, isocitrate lyase and malate synthase
(Kondrashov et al, 2006), making these enzymes promising and
specific antibacterial drug targets. Many years were spent unsuc-
cessfully trying to drug isocitrate lyase but progress was later made
with malate synthase. Elegant structure-based drug design was used
to develop potent phenyl-diketo acid inhibitors of malate synthase
that are active in a mouse model of TB (Krieger et al, 2012). This
study has chemically validated the glyoxylate pathway as a viable
new drug target and identified a lead series of compounds for
further preclinical development (Myler & Stacy, 2012).
Screening natural products
Natural products, notably streptomycin and rifampicin, have played
a considerable role in TB control. Despite the dominance of natural
product antibiotics for other bacterial infections, there were no new
natural product leads for mycobacteria until 2012 (Wright, 2012).
Recently, Hartkoorn et al (Hartkoorn et al, 2012) deciphered the
mechanism of action of pyridomycin, an antitubercular natural
product first discovered in 1953 (Maeda et al, 1953). After selection
of pyridomycin-resistant mutants followed by WGS, the authors
identified the INH target InhA as the target of pyridomycin
(Table 1). Since INH is a prodrug that requires activation by the cat-
alase-peroxidase KatG, resistance is most frequently associated with
mutations in the katG gene (Zhang & Yew, 2009). INH-resistant
clinical isolates harboring a mutation in katG retained sensitivity to
pyridomycin, making this natural product a promising lead com-
pound to target InhA in drug-resistant isolates and providing
encouragement for reinvestigation of natural product libraries using
novel approaches (Garcia et al, 2012).
Post-post-genomic screening strategies
Most whole-cell high throughput screens have been performed with
medium containing glycerol as the main carbon source, thus poorly
representing the environment Mtb encounters in the human host.
This can give rise to disappointment as exemplified by a recent
report (Pethe et al, 2010). Pyrimidine-imidazole derivatives with
promising in vitro potency and desirable pharmacokinetic properties
were identified using this medium but the hit compounds showed
no efficacy in vivo. Mechanism of action studies revealed the hits to
be active only in the glycerol-rich screening medium but not during
host infection where glycerol metabolism is less relevant (Pethe
et al, 2010). Thus, screening against Mtb under intracellular condi-
tions may yield hits with better in vivo activity and care should also
be taken in choosing the medium and mycobacterial species used
for the orthologous in vitro screen.
High content screening
High content screening using Mtb-infected macrophages exploits
automated confocal fluorescence microscopy to quantify intracellular
mycobacteria expressing GFP in a 384-well format (Christophe et al,
2009; Brodin & Christophe, 2011). This technique has several advan-
tages: (i) Putative hit compounds will target proteins that are
essential for intracellular survival which brings the screen closer to
the in vivo setting; (ii) Compounds with intracellular activity are
selected; (iii) Cytotoxic compounds with antimicrobial activity are
eliminated which saves time and money. Using this technique, Chris-
tophe et al screened 57 000 compounds for growth inhibition of Mtb
H37Rv-GFP in Raw264.7 macrophages (Christophe et al, 2009). Sev-
eral clusters of active molecules were identified. Among these were
the dinitrobenzamides (DNB1 and 2), discussed above, that are
inhibitors of DprE1, the BTZ-target. The screen identified additional
scaffolds with chemical structures unrelated to known antibacterials
which are currently under investigation. Among them was Q203, a
potent imidazopyridine amide derivative (Pethe et al, 2013).
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Screening against non-replicating bacteria
Yet another tactic to mimic in vivo conditions is screening under
low oxygen conditions. In granulomatous lesions, mycobacteria are
exposed to hypoxia which triggers a hypometabolic state leading to
a non-replicative persistence phase (Gengenbacher & Kaufmann,
2012). These dormant bacteria are tolerant to many antimycobacte-
rials, which is one reason for the lengthy duration of TB treatment.
Persisting mycobacteria have a reduced but still significant ATP-
pool which has to be maintained at low levels during dormancy
(Mak et al, 2012). A screen was developed to target this pool under
hypoxic conditions eventually thereby identifying compounds with
activity against non-replicating Mtb (Mak et al, 2012). 600 000 com-
pounds were screened against oxygen depleted Mycobacterium
bovis-BCG leading to the identification of 32 clusters of active com-
pounds that significantly reduce ATP-levels and show good MIC
against replicating and non-replicating mycobacteria.
Mtb harbors many proteins that are essential only during intra-
cellular infection and their characterization increases the number of
putative targets for future targeted drug screens. Bryk et al screened
for inhibitors of the dihydrolipoamide acyltransferase (DlaT), an
enzyme used by the bacterium to resist host derived nitric oxide
reactive oxygen intermediates (Bryk et al, 2008). Chemical screen-
ing for inhibitors of Mtb DlaT identified rhodanines as compounds
that kill almost exclusively non-replicating mycobacteria in synergy
with host immunity.
A simple approach to finding latency inhibitors is provided by
the streptomycin-dependent 18b strain of Mtb because, when strep-
tomycin is absent, 18b cannot grow and its metabolism shifts
towards latency (Sala et al, 2010). Streptomycin-starved 18b
(SS18b) has been used successfully for medium thoughput screens
with more extensive screening still in progress (Sala et al, 2010). A
major advantage of the SS18b model is its application to different
animal models thus allowing information about efficacy against
latency to be obtained in vivo. Using the SS18b system anti-TB drugs
and leads have been ranked and cell wall inhibitors shown to have
no efficacy in murine models whereas the drugs bedaquiline and
rifapentine performed exceptionally well (Zhang et al, 2012).
Target-based whole-cell screening
Target-based HTS and whole-cell HTS have their pros and cons.
Thus, efforts were made to combine both methods for the selection
of new compounds active against known targets. These target-based
whole-cell screens make use of tetracycline-repressible mycobacte-
rial promoters that allow the titrated expression of putative target
proteins (Ehrt et al, 2005). Reducing the levels of an essential pro-
tein may sensitize the bacterium towards an inhibitor that acts on
the down-regulated protein whereas wild-type bacteria should show
a higher MIC for the same compound allowing for hit identification.
Using this system, Abrahams et al generated conditional Mtb
knock-down mutants of the essential panC gene, which encodes
pantothenate synthase (Abrahams et al, 2012a). PanC is involved in
the biosynthesis of pantothenate (vitamin B5) and the respective
mutant is a pantothenate auxotroph and attenuated in mice. Condi-
tionally lowering PanC levels sensitized the bacteria towards a set of
PanC inhibitors identified using fragment-based approaches (Hung
et al, 2009; Abrahams et al, 2012a). A subsequent compound
library screen identified several flavones that showed 16-fold higher
activity against the panC-knockdown mutant compared to the
wild-type strain. Addition of pantothenate to the growth medium
abrogated this effect. Though the compounds showed no inhibition
of affinity-purified PanC in biochemical assays, it is likely that other
enzymes of the pantothenate pathway or pantothenate-requiring
enzymes are affected; this greatly reduces the number of putative
targets to be examined. Target-based whole-cell screening promises
to facilitate target validation for hit-compounds identified by
conventional whole-cell screens.
Cellular and animal models
The use of surrogate cells and mammalian hosts to mimick human
disease is fraught with difficulties so, while there is no commonly
accepted ‘gold standard’, pragmatism is required. For the purpose
of cell-based screening it is critical that the cells behave in a
robust and reproducible manner. Consequently, human or murine
cell lines such as THP-1 or Raw264.7, respectively, tend to be
favored over primary cells. Testing hit compounds for efficacy in
animal models is generally determined by the quantities of com-
pound available meaning that smaller animals, such as the mouse,
are preferred. A wide range of animal models exist that replicate
some but not all facets of human TB and the choice of species
depends largely on the question to be addressed (Young, 2009).
With respect to drug discovery and development the mouse again
figures prominently but it should be remembered that while drug
safety can be assessed in animal models drug efficacy is best
established in humans.
Manipulation of host functions
As an intracellular pathogen, Mtb exerts massive influence on the
gene expression of its host. More than 5000 genes are differentially
expressed in the lungs of Mtb-infected rabbits (Subbian et al, 2011).
In phagocytes, many of these genes are dedicated to an effective
immune response for clearing the pathogen yet Mtb is able to atten-
uate this host defense. Several siRNA screens have successfully
identified specific host genes and the underlying mechanisms
involved in dampening the microbicidal response (Kuijl et al, 2007;
Jayaswal et al, 2010; Kumar et al, 2010). Intriguingly, small mole-
cules can now be developed to abrogate the Mtb-induced alteration
of host cell-signaling in order to boost an effective response of the
immune system.
Antimicrobial drugs that target host protein kinases
Using siRNAs targeting kinases and phosphatases of mouse macro-
phages, 11 host enzymes were identified whose depletion led to a
reduction of the intracellular burden of various Mtb isolates (Jaya-
swal et al, 2010). Among these enzymes, the TGF-b type-1 receptor
(TGFbRI), a serine threonine kinase, was further confirmed as a
critical mediator for intracellular survival of Mtb by depletion of its
ligand (TGF-b) and by the finding that the bacterial burden in
Mtb-infected mice was lowered after treatment with D4476, a
TGFbRI inhibitor. TGF-b was confirmed as an attractive TB target in
a second, independent study where the lungs of chronically infected
mice were treated with siRNA targeting TGF-b1; this led to a modest
decrease of bacterial burden in C57/BL6 mice and, to a greater
degree, in IL-10 knock-out mice (Rosas-Taraco et al, 2011). Interest-
ingly, depletion of TGF-b, which inhibits the cell-mediated
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immunity stemming from the Th1 response during mycobacterial
infections, increased expression of the bactericidal nitric oxide
synthase (iNOS) and nitric oxide levels (Fig 2).
Another siRNA screen targeting the human kinome identified
AKT1 as a central mediator for survival and growth of intracellular
pathogens (Kuijl et al, 2007). Macrophage derived AKT1 is strongly
phosphorylated during bacterial infections and several AKT1 inhibi-
tors were shown to control intracellular replication of mycobacteria.
Kujil et al also performed siRNA-based pathway analysis identifying
a kinase network downstream of AKT1 as essential for phagosomal
maturation during infections with Salmonella typhimurium and Mtb.
This strategy may identify more target-specific kinase inhibitors, act-
ing downstream of AKT1, to control intracellular pathogens (Fig 2).
Yet another approach to identify regulatory networks of
intracellular pathogens is global gene expression profiling of the
infected host. Using this methodology, a Src tyrosine kinase was
shown to be a central regulator of Mtb intracellular survival
(Karim et al, 2011). Key to this finding was a comparative micro-
array study of macrophages infected with the fully virulent strain
H37Rv and the attenuated mutant H37Ra for up to 90 h. Src
kinase was downregulated and dephosphorylated during infection
with H37Ra but upregulated or unchanged during infection with
the wild-type strain. Subsequently, treatment of H37Rv-infected
macrophages with the Src-family kinase inhibitor PP2 promoted
phagolysosomal fusion and significantly reduced the intracellular
bacterial load in vitro.
Obviously, targeting innate immune signaling pathways may be
a risky way to eradicate pathogens capable of causing severe and
acute systemic infections. A therapeutic agent needs to be fine-tuned
to conserve a functional immune response yet counter pathogen
induced immune modeling throughout all stages of infection. The
cancer drug and BCR-Abl kinase inhibitor Imatinib (Gleevec,
Novartis, Basel, Switzerland) seems to fulfill most of these
prerequisites. A large number of viral and bacterial pathogens are
known to use the Abl-tyrosine kinase family to regulate pathogenic-
ity (Lebeis & Kalman, 2009). Treatment with Imatinib, which shows
a remarkably low toxicity profile during long term treatment of
chronic myelogenous leukemia patients (CML), was beneficial in
the control of poxvirus infections in mice (Reeves et al, 2005).
Recently, two independent studies have shown that the Abl tyrosine
kinase is a regulator of mycobacterial pathogenesis in macrophages
and Imatinib treatment reduces intracellular survival of Mtb in vitro
TNFα
D4476
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H-89/
PP2
vATPase
BCR-Abl
TGFβR
AKT1/
Src H
+
H+
CC-3052
iNOS
STRESS RESPONSE
Nucleus
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Figure 2. Modulation of the macrophage driven host response by Mycobacterium tuberculosis and the abrogation through compounds.
Mtb infection leads to the phosphorylation of AKT1 and upregulation of the Src-kinase which inhibits phago-lysosomal fusion. Subsequently, the AKT-inhibitor H-89 as well as
the Src-kinase inhibitor PP2 promotes fusion of theMtb phagosome with the lysosome. In addition, infected macrophages release TGF-b resulting in decreased levels of nitric
oxide synthase (iNOS) most likely through phosphorylation of the TGF-b receptor (TGFbR). Blockage of this receptor, for example with the compound D4476, releases nitric
oxide leading to enhanced clearance of the bacteria. Several pathogens (e.g. Shigella spp, Salmonella spp, Yersinia spp) are known to use the Abl-tyrosine-kinase to dampen a
successful antimicrobial host response. InMtb infected macrophages, blockage of this kinase with imatinib promotes acidification of the lysosome through up-regulation of
the proton pumping enzyme vacuolar-type H+-adenosine triphosphatase (vATPase) resulting in improved intracellular killing of Mtb. Infected macrophages release the pro-
inflammatory cytokine TNF-a. Though this cytokine promotes an antimycobacterial macrophage response, it also provokes a stress response in the bacteria with upregulation
of the Dos-regulon facilitating the transition to metabolically inactive bacteria and persistence. Blockage of TNF-a by the compound CC-3052 alleviates this stress and may
render the bacterial cells more susceptible to antimycobacterials such as isoniazid.
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(Napier et al, 2011; Bruns et al, 2012). Abl tyrosine kinase
influences trafficking of lysosomes and blockage of the kinase signif-
icantly increased the acidification of intracellular vesicles, most
likely by up-regulating the proton-pumping vacuolar-type ATPase
(vATPase; Bruns et al, 2012). Subsequently, bactericidal proteases
which are dependent on an acidic environment show enhanced
activity leading to better control of intracellular Mtb. Since Imatinib
treatment reduced bacterial burden in the lungs of Mtb-infected
mice, further evaluation of this FDA-approved drug is warranted
(Napier et al, 2011; Fig 2).
Controlling cytokines in the infected host
The bactericidal role of pro-inflammatory cytokines in the Mtb-
infected host is well established. Under certain clinical settings how-
ever, the pleiotropic effects of cytokines such as TNF-a can lead to a
hyperinflammatory response, massive tissue damage and disease
aggravation (Roca & Ramakrishnan, 2013). The immune reconstitu-
tion inflammatory syndrome (IRIS) that appears shortly after initiat-
ing anti-retroviral therapy in HIV-TB co-infected patients requires
therapeutic interventions to abrogate the noxious effect of TNF-a.
CC-3025, a phosphodiesterase-4 inhibitor and thalidomide analogue,
is a potent inhibitor of TNF-a production. Interestingly, co-treatment
of Mtb-infected rabbits with CC-3052 increases the bactericidal
activity of INH (Subbian et al, 2011). An extensive transcriptomic
study performed on both infected lung tissue and the pathogen
revealed a possible mechanism for the observed synergy. It was
shown that: (i) lung infection with Mtb leads to massive induction
of host genes, including several in the TNF-a network and TNF-a
itself; (ii) in turn Mtb upregulates the general stress response and
dormancy (dosR) regulons; (iii) INH-treatment promotes additional
upregulation of the genes for the drug target, InhA, the activator,
KatG, and other proteins involved in INH resistance; (iv) co-treat-
ment with CC-3052 reduces cytokine expression levels, including
TNF-a, which alleviates the bacterial stress response and, most
interestingly, reduces expression levels of INH-induced genes. Thus
CC-3052 treatment leads to bacterial cells which are metabolically
active and more susceptible towards antibiotics.
There is also growing evidence that severity of disease and
hyperinflammation is not only mediated by strain-specific virulence
but also by host-encoded susceptibility (Ganachari et al, 2012;
Tobin et al, 2012). SNPs found in the human leukotriene A4 hydro-
lase (LTA4H) locus illustrate the importance of a balanced pro-
and anti-inflammatory response towards Mtb. LTA4H catalyzes the
production of leukotriene B4, an eicosanoid that induces pro-
inflammatory cytokines such as TNF-a. SNPs negatively affecting
enzyme activity lead to an impaired immune response, more
severe disease and higher mortality (Tobin et al, 2010). However,
promoter polymorphisms positively affecting LTA4H expression
increase inflammation leading to higher mortality in patients with
tuberculous meningitis—a severe form of the disease that requires
adjunctive anti-inflammatory treatment with glucocorticoids. Inter-
estingly, patients with TB-meningitis who are homozygous for
LTA4H promoter mutations may primarily benefit from adjuvant
corticosteroid therapy (Tobin et al, 2012). This finding shows that
knowledge of the patients’ genotype not only provides information
about susceptibility towards the disease, but may also allow tai-
lored therapies for subsets of patients. This is also of major interest
in the light of several clinical studies on adjunct immunotherapy
with thalidomide, IL-2 or Mycobacterium vaccae, which failed to
show significant beneficial effects for the patients (Schoeman et al,
2004; Uhlin et al, 2012). Deeper knowledge of the genetic back-
ground of patients enrolled in future studies may result in more
favorable results.
Another SNP that influences the outcome of patients under cer-
tain circumstances is the t allele of the TaqI vitamin D receptor poly-
morphism. Though this non-synonymous SNP has no influence on
vitamin D serum levels, a double-blind randomized controlled trial
revealed that homozygous carriers showed faster sputum culture
conversion when vitamin D3 was co-administered during the
intensive-phase-treatment of pulmonary TB (Martineau et al, 2011).
An ongoing series of clinical trials may identify additional patient
subsets that could benefit from vitamin D3 substitution. Vitamin D
deficiency is common in patients with active TB and the immuno-
modulatory effects of supplementation are pleiotropic and hard to
interpret (Coussens et al, 2012). Bedside to bench research has
since revealed that the IFN-c-mediated antimycobacterial response
of human macrophages is highly dependent on sufficient vitamin D3
serum levels (Fabri et al, 2011). Incubation of human monocytes
with vitamin D-deficient serum abolished the IFN-c dependent
induction of antimicrobial peptides and blocked autophagolysoso-
mal fusion thereby causing uncontrolled growth of intracellular
bacilli. These effects were reversed when the cells were treated with
vitamin D-sufficient serum.
Concluding remarks
Research performed during the post-genomic era has successfully
generated leads and candidate drugs for the treatment of TB. A rea-
sonable drug development pipeline has arisen and there are grounds
for cautious optimism provided that attrition of the current candi-
dates can be managed, new leads are optimized and funding is
sustained to ensure that their development is completed. Intrigu-
ingly, several promiscuous targets were uncovered during the
post-genomic era and it is not clear if this were due to inherent prop-
erties of the proteins themselves or to the screening conditions and
compound libraries used. There is hope that the more diverse tech-
nological approach to screening currently being applied will deliver
additional targets, expand the compound classes and provide further
drug candidates to ensure that the TB drug pipeline remains filled
Pending issues
Translating IC50 into MIC.
Designing whole-cell screens to avoid promiscuous targets.
Developing an algorithm to predict in vivo efficacy.
Combining candidate drugs with existing agents while ensuring
compatibility with anti-retroviral drugs and simplifying clinical trials.
Minimizing potential side effects of host modifying agents, especially
in HIV/TB co-infection or when used as adjunct therapy.
Better understanding of host-pathogen interaction is required to
design targeted drugs, to optimize drug penetrance and to manipulate
non-productive host responses.
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and gains in robustness. Although intellectually appealing and sup-
ported by a growing number of successes, targeting host functions is
not without its problems. Foremost amongst these, of course, is tox-
icity due to the off-target effects of such inhibitors. However, in the
context of MDR-TB, there may well be a case for their compassionate
use together with an optimized background regime.
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